Unity Biotechnology raises $116M with Bezos backing to build anti-aging drugs

Unity Biotechnology develops drugs that clear senescent cells — aging cells linked to chronic disease — by repurposing apoptosis-inducing drug candidates from cancer research into a standard drug-development pipeline.

That clearing senescent cells could treat age-related disease, and that repurposed oncology drug candidates made it a standard pipeline blue-chip backers would fund.

$116M Series B announced around 2016-10-27, with backing Bloomberg credited to Jeff Bezos.

By late 2016 Unity Biotechnology was, in the description of a detailed commenter on its own funding thread, arguably the most mainstream of the startups targeting the clearance of senescent cells as a rejuvenation therapy — a company characterized by high-profile relationships with noted laboratories, venture groups and big names in the field. The approach rested on research going back decades: senescent cells accumulate with age and, even at about one percent of a tissue, secrete signals that disrupt structure and behavior, while remaining few enough to clear without major disruption.

The company's $116M Series B financing was announced around 2016-10-27, timed with its latest published research on senescent cells in atherosclerosis pathology, a pattern one commenter approvingly noted. Bloomberg's coverage credited the round with backing from Jeff Bezos. The discussion framed Unity as following the standard playbook for a hot drug company — repurposing apoptosis-inducing drug candidates to clear senescent cells — while skeptics argued that senescent cells are an evolved anti-cancer mechanism, so clearing them could trade aging for cancer, and that investors might really be betting on a cancer-adjacent market rather than rejuvenation.

Unity treated aging like any other indication, using a standard biotech pipeline of repurposed oncology drugs instead of a fountain-of-youth pitch.

The science had momentum in 2016: senescent-cell clearance had shown life-extension and tissue-repair data in mice, cited in the funding thread.

A $116M Series B with Bezos backing told the market that credible investors would fund rejuvenation science, not just supplements.

Skeptics framed the tradeoff: senescent cells are an evolved anti-cancer mechanism, so the same bet could be read as a cancer bet in disguise.

An unproven field can raise like a proven one when packaged as an ordinary drug developer — Unity's repurposed pipeline let blue-chip backers put $116M behind senescent-cell science.

As of 2016-10-27, the date this entry's sources cover, Unity Biotechnology had just announced the $116M Series B and was in the building stage of a standard drug-development pipeline: repurposing apoptosis-inducing drug candidates to clear senescent cells, with published atherosclerosis research accompanying the raise. The sources record no clinical product and no later milestones for the company.